

# Plegridy™ (peginterferon $\beta$ 1a) Real World Effectiveness and Safety Observational Program (POP)

**First published:** 29/01/2019

**Last updated:** 02/07/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS27459

---

### Study ID

48914

---

### DARWIN EU® study

No

---

### Study countries

 Australia

 Austria

 Canada

 Denmark

-  France
  -  Germany
  -  Ireland
  -  Italy
  -  Netherlands
  -  Portugal
  -  Spain
  -  Switzerland
  -  United Kingdom
  -  United States
- 

## **Study description**

The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice. The secondary objectives of this study in this study population are to describe Plegridy prescription and utilization adherence patterns in routine clinical practice, to assess the specific long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice, to monitor the safety and tolerability of Plegridy in routine clinical practice by assessing the incidence of adverse events (AEs) of flu-like symptoms (FLS), injection site reactions (ISRs), and AEs (including laboratory abnormalities) leading to treatment discontinuation, to assess the effect of FLS on participant-reported effectiveness of, and satisfaction with, prophylactic management using a FLS-Visual Analog Scale (FLS-VAS), to evaluate the change in health-related quality of life (HRQoL), FLS, FLS-VAS, healthcare resource consumption, and treatment adherence over time.

---

## **Study status**

Finalised

## **Research institutions and networks**

## Institutions

### Biogen

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

Multiple centres: 172 centres are involved in the study

## Contact details

### Study institution contact

Study Director Biogen [ctr@biogen.com](mailto:ctr@biogen.com)

Study contact

[ctr@biogen.com](mailto:ctr@biogen.com)

### Primary lead investigator

Study Director Biogen

Primary lead investigator

## Study timelines

**Date when funding contract was signed**

Actual: 28/08/2013

---

**Study start date**

Actual: 12/11/2014

---

**Date of final study report**

Planned: 14/06/2022

Actual: 01/08/2022

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Biogen

## Study protocol

[105MS401 Protocol V5 Final 16Apr2019\\_Redacted.pdf](#) (1.87 MB)

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

# Other study registration identification numbers and links

105MS401,,NCT02230969: <https://clinicaltrials.gov/ct2/show/NCT02230969>

## Methodological aspects

### Study type

#### Study type list

**Study topic:**

Disease /health condition  
Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Effectiveness study (incl. comparative)  
Safety study (incl. comparative)

**Data collection methods:**

Primary data collection

---

**Main study objective:**

The primary purpose of this study is to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical

effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice.

## Study Design

### **Non-interventional study design**

Cohort

Other

---

### **Non-interventional study design, other**

Prospective, global, observational study

## Study drug and medical condition

### **Medicinal product name**

PLEGRIDY

---

### **Medical condition to be studied**

Multiple sclerosis

## Population studied

### **Short description of the study population**

Patients with multiple sclerosis (MS) aged 18 years or older, who were newly and currently prescribed Plegridy according to the local label under routine clinical care. The study also included patients participated in the Study 105MS302 (ATTAIN) or Study 105MS303 (ALLOW). The patients were identified

from 160 sites in multiple regions, including the US, the United Kingdom (UK), the EU, Australia, Canada.

Inclusion criteria:

- Patient and or legal representative is willing and able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
- Patient with MS who is newly, or is currently, prescribed Plegridy according to local label including patients who participated in Study 105MS302 or Study105MS303.
- Patient age 18 years or older.
- Patient willing and able to complete PROs with minimal assistance.

Exclusion criteria:

- Concurrent enrollment in any clinical trial of an investigational product. Participation in non interventional study can be allowed as long as this participation does not interfere with this protocol or is likely to affect the patient's ability to comply with the protocol.
- 

### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Special population of interest**

Other

---

## **Special population of interest, other**

Patients with multiple sclerosis

---

## **Estimated number of subjects**

1208

# Study design details

## **Outcomes**

Safety of Plegridy will be evaluated by assessment of the incidence proportion and incidence rate of SAEs, Effectiveness of Plegridy on clinical no evidence of disease activity (cNEDA) will be evaluated by assessment of the proportion of patients with no relapses and no disability progression. Plegridy prescription and utilization adherence patterns, specific long-term clinical effectiveness of Plegridy, safety and tolerability of Plegridy, effect of FLS on patient-reported effectiveness of and satisfaction with prophylactic management using a FLS-Visual Analog Scale (VAS), change in HRQoL, FLS, FLS-VAS, healthcare resource consumption, and treatment adherence over time.

---

## **Data analysis plan**

Descriptive analyses will be performed to gain a better understanding of the qualitative and quantitative nature of the data collected and the characteristics of the sample studied. Categorical variables will be summarized as number and proportion of the total study population and by subgroups where appropriate. Continuous variables will be reported as mean (and standard deviation) or median and range, where appropriate. Categorical outcomes on healthcare resource consumption, treatment adherence, patient determined disease steps (PDDS), and Plegridy prescription and utilization patterns will be summarized using frequencies and percentages. If necessary, a 95% CI based on binomial distribution might be provided for some of the categorical variables like patient

adherence.

## Documents

### Study results

[105MS401 CSR Full V1 Synopsis 01Aug22\\_Redacted.pdf](#) (275.2 KB)

---

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

[Other](#)

---

### Data sources (types), other

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No